10. Antigen Discovery for Vaccines Using High-Throughput Proteomic Screening Technologies

  1. W. John W. Morrow PhD, DSc, FRCPath1,
  2. Nadeem A. Sheikh PhD2,
  3. Clint S. Schmidt PhD3,
  4. D. Huw Davies PhD4
  1. D. Huw Davies PhD

Published Online: 20 JUN 2012

DOI: 10.1002/9781118345313.ch10

Book Title

Vaccinology: Principles and Practice

Vaccinology: Principles and Practice

Additional Information

How to Cite

Davies, D. H. (2012) Antigen Discovery for Vaccines Using High-Throughput Proteomic Screening Technologies, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch10

Editor Information

  1. 1

    Seattle, WA, USA

  2. 2

    Dendreon Corporation, Seattle, WA, USA

  3. 3

    NovaDigm Therapeutics, Inc., Grand Forks, ND, USA

  4. 4

    University of California at Irvine, Irvine, CA, USA

Author Information

  1. University of California at Irvine, Irvine, CA, USA

Publication History

  1. Published Online: 20 JUN 2012
  2. Published Print: 3 AUG 2012

ISBN Information

Print ISBN: 9781405185745

Online ISBN: 9781118345313

SEARCH

CHAPTER TOOLS

Get PDF (164K)

Keywords:

  • antigen discovery;
  • high throughput screening;
  • proteome;
  • ORFeome;
  • transcriptome;
  • protein microarray;
  • IVTT

Summary

Recent progress in defining genomic, transcriptomic, and proteomic profiles of human pathogens promise to revolutionize vaccine development. Antigen discovery by traditional biochemical approaches is generally piecemeal and time consuming. These are being replaced by technologies that allow proteomes to be mined for reactive antibody and T-cell antigens in a comprehensive and unbiased fashion. Moreover, naturally acquired or vaccine-induced immunity can now be subjected to a systems biology approach to define the antigens than confer protection. In this chapter, high throughput (HT) proteomic screening technology for vaccine antigen discovery will be reviewed. Future challenges for translation of data obtained by HT screening into vaccines will also be discussed.

Get PDF (164K)